135 related articles for article (PubMed ID: 7591214)
21. Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers.
Stangelberger A; Schally AV; Varga JL; Hammann BD; Groot K; Halmos G; Cai RZ; Zarandi M
Prostate; 2005 Aug; 64(3):303-15. PubMed ID: 15754342
[TBL] [Abstract][Full Text] [Related]
22. Effect of the gastrin-releasing peptide antagonist BIM 26226 and lanreotide on an acinar pancreatic carcinoma.
Damgé C; Hajri A
Eur J Pharmacol; 1998 Apr; 347(1):77-86. PubMed ID: 9650851
[TBL] [Abstract][Full Text] [Related]
23. Potentiation of the inhibitory effect of growth hormone-releasing hormone antagonists on PC-3 human prostate cancer by bombesin antagonists indicative of interference with both IGF and EGF pathways.
Plonowski A; Schally AV; Varga JL; Rekasi Z; Hebert F; Halmos G; Groot K
Prostate; 2000 Jul; 44(2):172-80. PubMed ID: 10881027
[TBL] [Abstract][Full Text] [Related]
24. Somatostatin analog RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 inhibit the growth of androgen-independent DU-145 human prostate cancer line in nude mice.
Pinski J; Halmos G; Schally AV
Cancer Lett; 1993 Jul; 71(1-3):189-96. PubMed ID: 8103419
[TBL] [Abstract][Full Text] [Related]
25. Combination of gastrin-releasing peptide antagonist with cytotoxic agents produces synergistic inhibition of growth of human experimental colon cancers.
Rick FG; Buchholz S; Schally AV; Szalontay L; Krishan A; Datz C; Stadlmayr A; Aigner E; Perez R; Seitz S; Block NL; Hohla F
Cell Cycle; 2012 Jul; 11(13):2518-25. PubMed ID: 22751419
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of growth of ES-2 human ovarian cancers by bombesin antagonist RC-3095, and luteinizing hormone-releasing hormone antagonist Cetrorelix.
Chatzistamou I; Schally AV; Szepeshazi K; Groot K; Hebert F; Arencibia JM
Cancer Lett; 2001 Sep; 171(1):37-45. PubMed ID: 11485826
[TBL] [Abstract][Full Text] [Related]
27. Effect of bombesin, gastrin-releasing peptide (GRP)(14-27) and bombesin/GRP receptor antagonist RC-3095 on growth of nitrosamine-induced pancreatic cancers in hamsters.
Szepeshazi K; Schally AV; Groot K; Halmos G
Int J Cancer; 1993 May; 54(2):282-9. PubMed ID: 8387464
[TBL] [Abstract][Full Text] [Related]
28. Powerful inhibition of in-vivo growth of experimental hepatic cancers by bombesin/gastrin-releasing peptide antagonist RC-3940-II.
Szepeshazi K; Schally AV; Rick FG; Block NL; Vidaurre I; Halmos G; Szalontay L
Anticancer Drugs; 2012 Oct; 23(9):906-13. PubMed ID: 22926257
[TBL] [Abstract][Full Text] [Related]
29. Antagonists of bombesin/gastrin-releasing peptides as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer.
Pinski J; Halmos G; Szepeshazi K; Schally AV
Cancer; 1993 Dec; 72(11):3263-70. PubMed ID: 8242552
[TBL] [Abstract][Full Text] [Related]
30. Inhibitory effect of antagonists of bombesin and growth hormone-releasing hormone on orthotopic and intraosseous growth and invasiveness of PC-3 human prostate cancer in nude mice.
Stangelberger A; Schally AV; Varga JL; Zarandi M; Szepeshazi K; Armatis P; Halmos G
Clin Cancer Res; 2005 Jan; 11(1):49-57. PubMed ID: 15671527
[TBL] [Abstract][Full Text] [Related]
31. Antagonists of bombesin/gastrin-releasing Peptide inhibit growth of jar human choriocarcinoma cells and production of cyclic-amp in-vitro.
Ertl T; Qin Y; Groot K; Horvath J; Cai R; Schally A
Int J Oncol; 1995 Mar; 6(3):547-53. PubMed ID: 21556569
[TBL] [Abstract][Full Text] [Related]
32. Bombesin antagonists inhibit growth of MDA-MB-435 estrogen-independent breast cancers and decrease the expression of the ErbB-2/HER-2 oncoprotein and c-jun and c-fos oncogenes.
Bajo AM; Schally AV; Krupa M; Hebert F; Groot K; Szepeshazi K
Proc Natl Acad Sci U S A; 2002 Mar; 99(6):3836-41. PubMed ID: 11891317
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of the growth of Caki-I human renal adenocarcinoma in vivo by luteinizing hormone-releasing hormone antagonist Cetrorelix, somatostatin analog RC-160, and bombesin antagonist RC-3940-II.
Jungwirth A; Schally AV; Halmos G; Groot K; Szepeshazi K; Pinski J; Armatis P
Cancer; 1998 Mar; 82(5):909-17. PubMed ID: 9486581
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of mutant p53 expression and growth of DMS-153 small cell lung carcinoma by antagonists of growth hormone-releasing hormone and bombesin.
Kanashiro CA; Schally AV; Groot K; Armatis P; Bernardino AL; Varga JL
Proc Natl Acad Sci U S A; 2003 Dec; 100(26):15836-41. PubMed ID: 14660794
[TBL] [Abstract][Full Text] [Related]
35. Inhibitory effect of bombesin/gastrin-releasing peptide antagonist RC-3095 and high dose of somatostatin analogue RC-160 on nitrosamine-induced pancreatic cancers in hamsters.
Szepeshazi K; Schally AV; Cai RZ; Radulovic S; Milovanovic S; Szoke B
Cancer Res; 1991 Nov; 51(21):5980-6. PubMed ID: 1682039
[TBL] [Abstract][Full Text] [Related]
36. RC-3095, a gastrin-releasing peptide receptor antagonist, synergizes with gemcitabine to inhibit the growth of human pancreatic cancer CFPAC-1 in vitro and in vivo.
Hong SK; Yang SY; Yin SH; Yang KX
Pancreas; 2014 Jan; 43(1):15-21. PubMed ID: 24326363
[TBL] [Abstract][Full Text] [Related]
37. Bombesin antagonists inhibit proangiogenic factors in human experimental breast cancers.
Bajo AM; Schally AV; Groot K; Szepeshazi K
Br J Cancer; 2004 Jan; 90(1):245-52. PubMed ID: 14710236
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of growth of HT-29 human colon cancer xenografts in nude mice by treatment with bombesin/gastrin releasing peptide antagonist (RC-3095).
Radulovic S; Miller G; Schally AV
Cancer Res; 1991 Nov; 51(21):6006-9. PubMed ID: 1682040
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist Cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II.
Jungwirth A; Pinski J; Galvan G; Halmos G; Szepeshazi K; Cai RZ; Groot K; Vadillo-Buenfil M; Schally AV
Eur J Cancer; 1997 Jun; 33(7):1141-8. PubMed ID: 9376196
[TBL] [Abstract][Full Text] [Related]
40. High potency of a new bombesin antagonist (RC-3095) in inhibiting serum gastrin levels; comparison of different routes of administration.
Pinski J; Yano T; Rekasi Z; Cai RZ; Radulovic S; Schally AV
Regul Pept; 1992 Oct; 41(3):185-93. PubMed ID: 1438988
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
